Rebuilding trust in proton pump inhibitor therapy
暂无分享,去创建一个
[1] S. Spechler,et al. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. , 2021, The American journal of gastroenterology.
[2] Die Fan,et al. No Associations Between Regular Use of Proton Pump Inhibitors and Risk of All-Cause and Cause-Specific Mortality: A Population-Based Cohort of 0.44 Million Participants , 2021, The American journal of gastroenterology.
[3] A. Barkun,et al. Proton pump inhibitors and risk of gastric cancer: population-based cohort study , 2021, Gut.
[4] A. Barkun,et al. ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding , 2021, The American journal of gastroenterology.
[5] P. Paśko,et al. Effect of Food and Dosing Regimen on Safety and Efficacy of Proton Pump Inhibitors Therapy—A Literature Review , 2021, International journal of environmental research and public health.
[6] Z. McMahan,et al. A practical approach to the evaluation and management of gastrointestinal symptoms in patients with systemic sclerosis. , 2021, Best practice & research. Clinical rheumatology.
[7] M. Melbye,et al. Proton-Pump Inhibitor Use and the Risk of Community-Associated Clostridium difficile Infection , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] R. Valera,et al. Adverse Effects Associated with Proton Pump Inhibitor Use , 2021, Cureus.
[9] J. Schold,et al. Proton-pump inhibitor vs. H2-receptor blocker use and overall risk of CKD progression , 2020, BMC Nephrology.
[10] J. Pandolfino,et al. AMBULATORY REFLUX MONITORING GUIDES PROTON PUMP INHIBITOR DISCONTINUATION IN PATIENTS WITH GASTROESOPHAGEAL REFLUX SYMPTOMS: A CLINICAL TRIAL. , 2020, Gastroenterology.
[11] E. Savarino,et al. EFFICACY OF THERAPY FOR EOSINOPHILIC ESOPHAGITIS IN REAL-WORLD PRACTICE. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[12] M. Walker,et al. Educational Intervention Improves Proton Pump Inhibitor Stewardship in Outpatient Gastroenterology Clinics , 2019, Gastroenterology research.
[13] J. Cooke,et al. Cardiovascular Risk of Proton Pump Inhibitors. , 2019, Methodist DeBakey cardiovascular journal.
[14] W. Leung,et al. Long-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence , 2019, Therapeutic advances in gastroenterology.
[15] Avinash B. Kumar,et al. The risks of long-term use of proton pump inhibitors: a critical review , 2018, Therapeutic advances in drug safety.
[16] A. Hoes,et al. Use of proton pump inhibitors and risk of iron deficiency: a population‐based case–control study , 2018, Journal of internal medicine.
[17] Prashanth Rawla,et al. Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors? , 2018, World journal of gastrointestinal pharmacology and therapeutics.
[18] Kelley E. Capocelli,et al. Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. , 2018, Gastroenterology.
[19] D. Graham. Optimal PPI Dosing for Improving GERD Symptoms: Is Timing Everything? , 2018, Digestive Diseases and Sciences.
[20] Yousef Nassar,et al. Proton-pump Inhibitor Use and Fracture Risk: An Updated Systematic Review and Meta-analysis , 2018, Journal of bone metabolism.
[21] J. Keller. What Is the Impact of High-Resolution Manometry in the Functional Diagnostic Workup of Gastroesophageal Reflux Disease , 2018, Visceral Medicine.
[22] C. Calderón-Ospina,et al. Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences , 2018, Neural plasticity.
[23] W. Lewis,et al. Outcomes after laparoscopic anti-reflux surgery related to obesity: A systematic review and meta-analysis. , 2018, International journal of surgery.
[24] K. Thavorn,et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[25] A. Ciobica,et al. Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis , 2017, World journal of gastroenterology.
[26] P. Moayyedi,et al. ACG and CAG Clinical Guideline: Management of Dyspepsia. , 2017, The American journal of gastroenterology.
[27] F. Bazzoli,et al. Proton pump inhibitors: Risks of long‐term use , 2017, Journal of gastroenterology and hepatology.
[28] K. Koh,et al. Proton pump inhibitors do not increase the risk for recurrent spontaneous bacterial peritonitis in patients with cirrhosis , 2017, Journal of gastroenterology and hepatology.
[29] S. Paterson-Brown,et al. Long‐term outcomes following laparoscopic anterior and Nissen fundoplication , 2017, ANZ journal of surgery.
[30] D. Freedberg,et al. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. , 2017, Gastroenterology.
[31] W. Chey,et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection , 2017, The American Journal of Gastroenterology.
[32] A. Bredenoord,et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults , 2017, United European gastroenterology journal.
[33] E. Savarino,et al. The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. , 2017, European journal of internal medicine.
[34] Shujie Chen,et al. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth , 2017, Journal of Gastroenterology.
[35] A. Hoes,et al. Use of Proton Pump Inhibitors and Risks of Fundic Gland Polyps and Gastric Cancer: Systematic Review and Meta-analysis. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[36] A. Zullo,et al. Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression , 2016, BMC Medicine.
[37] Jeffrey H William,et al. Magnesium Deficiency and Proton‐Pump Inhibitor Use: A Clinical Review , 2016, Journal of clinical pharmacology.
[38] L. Laine,et al. Long-Term PPI Use: Balancing Potential Harms and Documented Benefits , 2016, The American Journal of Gastroenterology.
[39] Wenjie Xiong,et al. Proton pump inhibitor therapy and its association with spontaneous bacterial peritonitis incidence and mortality: A meta-analysis. , 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[40] Josef Coresh,et al. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. , 2016, JAMA internal medicine.
[41] Nicholas J Shaheen,et al. ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus , 2016, The American Journal of Gastroenterology.
[42] J. Lam,et al. Risk of Community-Acquired Pneumonia with Outpatient Proton-Pump Inhibitor Therapy: A Systematic Review and Meta-Analysis , 2015, PloS one.
[43] Y. Huang,et al. Proton-pump inhibitors and risk of fractures: an update meta-analysis , 2015, Osteoporosis International.
[44] Eun Hye Kim,et al. The Association between the Use of Proton Pump Inhibitors and the Risk of Hypomagnesemia: A Systematic Review and Meta-Analysis , 2014, PloS one.
[45] M. Klemp,et al. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis , 2014, BMJ Open.
[46] R. Fanelli,et al. Guidelines for the management of hiatal hernia , 2013, Surgical Endoscopy.
[47] E. Dellon,et al. Clinical Guideline : Evidenced Based Approach to the Diagnosis and Management of Esophageal Eosinophilia and Eosinophilic Esophagitis ( EoE ) , 2013 .
[48] Sang Min Park,et al. Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies. , 2013, World journal of gastroenterology.
[49] J. Tajti,et al. The effects of laparoscopic Nissen fundoplication on Barrett's esophagus: Long-term results , 2012, Scandinavian Journal of Gastroenterology.
[50] T. G. Ellington,et al. Proton Pump Inhibitor Therapy Use Does Not Predispose to Small Intestinal Bacterial Overgrowth , 2011, The American Journal of Gastroenterology.
[51] J. Horn,et al. Clinical Pharmacology of Proton Pump Inhibitors , 2012, Drugs.
[52] Prateek Sharma,et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. , 2011, Gastroenterology.
[53] R. Jensen,et al. Association of Long-Term Proton Pump Inhibitor Therapy with Bone Fractures and Effects on Absorption of Calcium, Vitamin B12, Iron, and Magnesium , 2010, Current gastroenterology reports.
[54] H. Echizen,et al. Drug-Drug Interaction Profiles of Proton Pump Inhibitors , 2010, Clinical pharmacokinetics.
[55] N. Kassam,et al. Safety of the long-term use of proton pump inhibitors. , 2010, World journal of gastroenterology.
[56] E. Wittbrodt,et al. Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis , 2009, Clinical and experimental gastroenterology.
[57] F. Chan,et al. Guidelines for Prevention of NSAID-Related Ulcer Complications , 2009, The American Journal of Gastroenterology.
[58] N. Shaheen,et al. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. , 2008, Gastroenterology.
[59] J. Gregor,et al. Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials. , 2008, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[60] B. Batuwitage,et al. Inappropriate prescribing of proton pump inhibitors in primary care , 2007, Postgraduate Medical Journal.
[61] Yu-Xiao Yang,et al. Long-term proton pump inhibitor therapy and risk of hip fracture. , 2006, JAMA.
[62] C. Scarpignato,et al. Review article: the opportunities and benefits of extended acid suppression , 2006, Alimentary pharmacology & therapeutics.
[63] G. Sachs,et al. Review article: the clinical pharmacology of proton pump inhibitors , 2006, Alimentary pharmacology & therapeutics.
[64] H. Blume,et al. Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors , 2006, Drug safety.
[65] B. Cooper,et al. Oesophageal pH monitoring in Barrett's oesophagus , 2003, Gut.
[66] C. Stedman,et al. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors , 2000, Alimentary pharmacology & therapeutics.
[67] T. Ishizaki,et al. Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazole , 1999, Alimentary pharmacology & therapeutics.
[68] Stewart,et al. Iron absorption in patients with Zollinger–Ellison syndrome treated with long‐term gastric acid antisecretory therapy , 1998, Alimentary pharmacology & therapeutics.